Biogen Aktie - 1BIIB

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Current Price

130,65

Gebot

130,25

Fragen

145,90

Volumen

130,50 Tagesbereich 138,45

125,25 52-Wochen-Bereich 220,70

Marktkapitalisierung

19,124B

Handelsende

142,80

Handelsbeginn

138,00

Letzte Trade

130.5

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

Ausgegebene Aktien

146.374.937

Dividendenrendite

Kurs-Gewinn-Verhältnis

12,88

Gewinn pro Aktie (EPS)

11,15

Erlöse

9,68B

Nettogewinn

1,63B

Sektor

Biological Pds,ex Diagnstics

Branche

Biological Pds,ex Diagnstics

Website

www.biogen.com

Hauptsitz

Wilmington, Delaware, USA

Gegründet

Biogen Inc is listed in the Biological Pds,ex Diagnstics sector of the Italienische Börse with ticker 1BIIB. The last closing price for Biogen was 142,80 €. Over the last year, Biogen shares have traded in a share price range of 125,25 € to 220,70 €.

Biogen currently has 146.374.937 shares in issue. The market capitalisation of Biogen is 20,90 € billion. Biogen has a price to earnings ratio (PE ratio) of 12.88.

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients Global...

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare...

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union TOKYO and CAMBRIDGE, Mass., Jan. 31, 2025 (GLOBE...

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Once every four weeks maintenance...

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA Applications are based on data from the DEVOTE study, which...

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s...

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus...

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease TOKYO and CAMBRIDGE, Mass., Nov...

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD...

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	-8.2	-5.905653583	138.85	145.05	130.5	54	142.57837209	DE
4	-5.85	-4.28571428571	136.5	145.05	125.25	95	133.76061141	DE
12	-14.55	-10.020661157	145.2	149.4	125.25	76	138.63287966	DE
26	-49.2	-27.3561301084	179.85	182	125.25	61	147.01773244	DE
52	-72.75	-35.7669616519	203.4	220.7	125.25	49	162.56078391	DE
156	-84.95	-39.4016697588	215.6	244.6	125.25	44	167.33585852	DE
260	-84.95	-39.4016697588	215.6	244.6	125.25	44	167.33585852	DE

1BIIB - Frequently Asked Questions (FAQ)

What is the current Biogen share price?

The current share price of Biogen is 130,65 €

How many Biogen shares are in issue?

Biogen has 146.374.937 shares in issue

What is the market cap of Biogen?

The market capitalisation of Biogen is EUR 20,9B

What is the 1 year trading range for Biogen share price?

Biogen has traded in the range of 125,25 € to 220,70 € during the past year

What is the PE ratio of Biogen?

The price to earnings ratio of Biogen is 12,88

What is the cash to sales ratio of Biogen?

The cash to sales ratio of Biogen is 2,17

What is the reporting currency for Biogen?

Biogen reports financial results in USD

What is the latest annual turnover for Biogen?

The latest annual turnover of Biogen is USD 9,68B

What is the latest annual profit for Biogen?

The latest annual profit of Biogen is USD 1,63B

What is the registered address of Biogen?

The registered address for Biogen is 3411 SILVERSIDE ROAD TATNALL, BUILDING #104, NEW CASTLE, WILMINGTON, DELAWARE, 19810

What is the Biogen website address?

The website address for Biogen is www.biogen.com

Which industry sector does Biogen operate in?

Biogen operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
EPHEPH SpA	0,102 € (30,77%)	876,15k
1NLOKGen Digital Inc	25,00 € (28,87%)	78
MPTImpianti SpA	0,975 € (21,88%)	441k
1IDRIndra Sistemas	28,66 € (14,92%)	800
NTWNetweek SpA	0,0324 € (10,20%)	981,69k
WFAE25Fae Technology	0,25 € (-19,35%)	1,34k
1HFGHelloFresh SE	8,248 € (-16,77%)	7,74k
1ESSIEssity AB	23,54 € (-14,09%)	200
1MRNAModerna Inc	30,155 € (-11,85%)	19,17k
1HEN3Henkel AG & Co KGAA	77,50 € (-11,43%)	46
TITTelecom Italia SpA	0,2691 € (-2,07%)	229,24M
ISPIntesa Sanpaolo Spa	4,6835 € (-2,22%)	77,42M
SPMSaipem Spa	1,9635 € (-0,73%)	36,68M
ENELEnel Spa	6,943 € (0,04%)	31,72M
STLAMStellantis NV	11,312 € (-5,32%)	26,21M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Biogen Inc (1BIIB)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

Über Biogen Inc

1BIIB Neueste Nachrichten

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

1BIIB - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Biogen Inc (1BIIB) Börsenkurse

Biogen Inc (1BIIB)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

Über Biogen Inc

1BIIB Neueste Nachrichten

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

1BIIB - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen